The role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review

References

• Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol. 1997;38(3):115–123.
   PubMedGoogle Scholar
• Yoldemir T. Postmenopausal hyperandrogenism. Climacteric. 2022;25(2):109–117.
   PubMed Web of Science ®Google Scholar
• Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial atrophic acne scars on quality of life: a multi-country Population-Based survey. Am J Clin Dermatol. 2022;23(1):115–123.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.e933.
   PubMed Web of Science ®Google Scholar
• https://www.ema.europa.eu/en/news/dienogestethinylestradiol-can-be-used-acne-after-certain other-treatments-have-failed
   Google Scholar
• Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51(6):341–346.
   PubMed Web of Science ®Google Scholar
• Greco T, Graham CA, Bancroft J, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinylestradiol. Contraception. 2007;76(1):8–17.
   PubMed Web of Science ®Google Scholar
• Sulak P, Lippman J, Siu C, et al. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Contraception. 1999;59(3):161–166.
   PubMed Web of Science ®Google Scholar
• Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89(4):615–622.
   PubMed Web of Science ®Google Scholar
• Janaud A, Rouffy J, Upmalis D, et al. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl. 1992;156:33–38.
   PubMedGoogle Scholar
• Lucky AW, Henderson TA, Olson WH, et al. EIectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37(5 Pt 1):746–754.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Chaovisitsaree S, Angsuwathana S, et al. A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial. Contraception. 2014;90(5):535–541.
   PubMed Web of Science ®Google Scholar
• Thorneycroft L, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74(2):123–130.
   PubMed Web of Science ®Google Scholar
• Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, et al. Acne vulgaris. Nat Rev Dis Primers. 2015;1:15029.
   PubMed Web of Science ®Google Scholar
• Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol. 2015;172(Suppl 1):37–46.
   PubMedGoogle Scholar
• Lai JJ, Chang P, Lai KP, et al. The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res. 2012;304(7):499–510.
   PubMed Web of Science ®Google Scholar
• Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;(7):CD004425.
   Web of Science ®Google Scholar
• Pasquale S. Rationale for a triphasic oral contraceptive. J Reprod Med. 1984;29(7 Suppl):560–567.
   PubMedGoogle Scholar
• Henzl MR. Norgestimate. From the laboratory to three clinical indications. J Reprod Med. 2001;46(7):647–661.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. 2014. https://www.ema.europa.eu/en/documents/referral/benefits-combined-hormonal-contraceptives chcs-continue-outweigh-risks_en.pdf
   Google Scholar
• Grandi G, Savio D, Facchinetti MC. F. The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism. Expert Rev Clin Pharmacol. 2021;14(2):211–224.
   PubMed Web of Science ®Google Scholar
• Coenen CM, Thomas CM, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171–176.
   PubMed Web of Science ®Google Scholar
• Hammond GL, Abrams LS, Creasy GW, et al. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• White T, Ozel B, Jain JK, et al. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception. 2006;74(4):293–296.
   PubMed Web of Science ®Google Scholar
• Chapdelaine A, Desmarais JL, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 1989;34(5):347–352.
   PubMedGoogle Scholar
• Paris F, Rabeolina F, Bacquet A, et al. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-trasfected cell line. Gynecol Endocrinol. 2007;23(4):193–197.
   PubMed Web of Science ®Google Scholar
• Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14(4):223–230.
   PubMed Web of Science ®Google Scholar
• Phillips A, Hahn DW, McGuire JL. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Steroid. 1990;55(8):373–375.
   PubMed Web of Science ®Google Scholar
• Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Inter J Fertil Women Med. 1998;43:286–290.
   PubMedGoogle Scholar
• Sator PG, Schmidt JB. Hönigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A Pilot Study. Dermatology. 2003;206(3):241.
   PubMed Web of Science ®Google Scholar
• Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008;58:60–62.
   PubMed Web of Science ®Google Scholar
• Lortscher D, Admani S, Satur N, et al. Hormonal contraceptives and acne: a retrospective analysis of 2147 patients. J Drugs Dermatol. 2016;15(6):670–674.
   PubMed Web of Science ®Google Scholar